Core Viewpoint - The company, Jiukang Bio, is a leading player in the in vitro diagnostic industry in China, focusing on the research, production, and sales of diagnostic products [1] Group 1: Company Overview - Jiukang Bio is recognized as a national high-tech enterprise [1] - The company offers a range of in vitro diagnostic products that are developed in line with international standards [1] Group 2: Product Offerings - The product portfolio includes pathology detection systems, biochemical detection systems, coagulation detection systems, luminescence detection systems, blood type detection systems, POCT detection systems, and liquid biopsy CTC [1] Group 3: Future Plans - The company indicated that any future developments in innovative drugs will be disclosed in accordance with information disclosure regulations [1]

Core Viewpoint - The company Jiukang Bio (300406.SZ) has received an update regarding the shareholding increase plan from its major shareholder, China National Pharmaceutical Group Investment Co., Ltd. [1] Group 1: Shareholding Increase - As of the announcement date, the shareholding increase plan has passed the halfway mark [1] - China National Pharmaceutical Group has acquired a total of 2,621,000 shares through centralized bidding, representing 0.45% of the company's voting shares [1] - The total amount invested in this share acquisition is approximately 35,696,359 RMB [1]

Core Viewpoint - China Medical Investment Co., Ltd., a major shareholder of Jiukang Bio (SZ 300406), plans to increase its stake in the company by investing at least 30 million RMB from June 23, 2025, to December 22, 2025, through various trading methods [1] Group 1: Shareholder Actions - The major shareholder has already increased its stake by approximately 2.62 million shares, representing 0.45% of the company's voting shares, with an investment amount of about 35.7 million RMB [1] - The increase in shareholding is part of a broader strategy to enhance the company's market position and investor confidence [1] Group 2: Company Financials - Jiukang Bio's revenue for the year 2024 is expected to be entirely derived from the healthcare sector, with a 100% contribution from this segment [1] - As of the announcement date, Jiukang Bio's market capitalization stands at 7.8 billion RMB [1]

| 证券代码：300406 | 证券简称：九强生物 | 公告编号：2025-081 | | --- | --- | --- | | 债券代码：123150 | 债券简称：九强转债 | | 北京九强生物技术股份有限公司 关于公司持股 5%以上股东增持公司股份计划实施期限过半的公告 持股 5%以上的股东中国医药投资有限公司保证向本公司提供的信息内容真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 1、增持计划的基本情况：持股 5%以上的股东中国医药投资有限公司（以下 简称"国药投资"或"增持主体"）计划自 2025 年 6 月 23 日至 2025 年 12 月 22 日，通过集中竞价交易、大宗交易等法律法规允许的方式增持公司股票，计 划增持公司股份金额不少于 3000 万元（含）人民币（含 2025 年 6 月 23 日已增 持部分），增持所需资金为自有资金。 2、增持实施情况：截至本公告披露日，本次增持计划实施期限已过半。增 持主体以集中竞价交易的方式共增持股份 2,621,000 股，占公司当前有表决权股 份比例 0.4 ...

Core Viewpoint - The company acknowledges the increasing penetration and accelerated technological iteration in the IVD industry, leading to more refined and specialized market competition, while regulatory policies are guiding the industry towards higher quality and compliance [1] Group 1: Industry Trends - The IVD industry is experiencing a gradual increase in penetration rates and rapid technological advancements [1] - Market competition is becoming more refined and specialized due to these changes [1] - Regulatory policies are promoting the industry towards higher quality and compliance [1] Group 2: Company Strategy - The company maintains a clear understanding of the industry dynamics and continues to focus on its core IVD sector [1] - The company is also exploring new directions with strong technological synergies and broad market potential in the medical device field [1] - The company aims to deliver solid performance to reward its investors in the future [1]

（文章来源：每日经济新闻） 九强生物（300406.SZ）9月19日在投资者互动平台表示，公司有"脑脊液/尿液总蛋白测定试剂盒"，目 前暂无骨髓方面的产品。 每经AI快讯，有投资者在投资者互动平台提问：请问贵司有没有免疫系统检测，检测脑液以及骨髓方 面的方法？试剂？ ...

Core Viewpoint - The company has decided not to lower the conversion price of its convertible bonds, "Jiuqiang Convertible Bonds," and will not propose any downward adjustments for the next six months [1] Summary by Relevant Sections - **Board Meeting Decision** - The fifth board meeting of the company on September 18, 2025, approved the proposal not to adjust the conversion price of "Jiuqiang Convertible Bonds" downwards [1] - **Future Conditions** - For the next six months, from September 19, 2025, to March 18, 2026, the company will not propose any downward adjustment even if the conditions for such an adjustment are triggered [1] - The next period for potential adjustment will start from March 19, 2026, which is the first trading day after the non-adjustment period ends [1] - **Future Board Meetings** - If the conditions for downward adjustment are triggered again, the board will convene to decide whether to exercise the right to adjust the conversion price [1]

Group 1 - Company Jiukang Bio announced the convening of its 18th meeting of the 5th Board of Directors on September 18, 2025, using a combination of on-site and remote voting methods [1] - The meeting reviewed the proposal regarding not to lower the conversion price of "Jiukang Convertible Bonds" [1]

| 证券代码：300406 | 证券简称：九强生物 | 公告编号：2025-080 | | --- | --- | --- | | 债券代码：123150 | 债券简称：九强转债 | | 北京九强生物技术股份有限公司 一、可转换公司债券基本情况 （一）可转换公司债券发行情况 经中国证券监督管理委员会《关于同意北京九强生物技术股份有限公司向不 特定对象发行可转换公司债券注册的批复》（证监许可〔2022〕1081 号）核准， 并经深圳证券交易所（以下简称"深交所"）创业板上市委 2022 年第 13 次上市 委员会审议会议审核通过。公司于 2022 年 6 月 30 日公开发行可转换公司债券（以 下简称"可转债"、"可转换公司债券"或"九强转债"）11,390,000 张，每 张面值 100 元（币种人民币，下同），募集资金总额为 113,900.00 万元，期限 6 年。本次发行的可转债向原股东优先配售，原股东优先配售后余额（含原股东 放弃优先配售部分）通过深交所交易系统向社会公众投资者发售的方式进行，认 购金额不足 113,900.00 万元的部分由保荐机构（联席主承销商）中国国际金融 股份有限公司包销。网上 ...

证券代码：300406 证券简称：九强生物 公告编号：2025-079 债券代码：123150 债券简称：九强转债 北京九强生物技术股份有限公司 第五届董事会第十八次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 北京九强生物技术股份有限公司(以下简称"公司")第五届董事 会第十八次会议（以下简称"本次会议"）于 2025 年 9 月 18 日在公 司会议室以现场表决和通讯表决相结合的方式召开。本次会议已于 2025 年 9 月 18 日以电话、电子邮件等方式通知全体董事。公司全体董 事均同意豁免本次董事会会议通知时限要求。会议由公司董事长邹左 军主持，董事刘希、罗爱平、孙小林、王小亚、陈永宏、杨建平、叶 军出席了会议。公司监事及高级管理人员列席了本次会议。 本次会议的通知、召集、召开和表决符合《中华人民共和国公司 法》等相关法律法规和《公司章程》的有关规定。 二、董事会会议审议情况 经与会董事充分讨论与审议，会议形成以下决议： 1、审议通过《关于不向下修正"九强转债"转股价格的议案》 本次触发转股价格向下修正条款的期间从 ...